{
  "thread": {
    "uuid": "62662f183b9ab44ca3a8f6a659a4bb538125d6de",
    "url": "https://finance.sina.com.cn/roll/2025-07-31/doc-infiitzy9202743.shtml",
    "site_full": "finance.sina.com.cn",
    "site": "sina.com.cn",
    "site_section": "http://finance.sina.com.cn/stock/",
    "site_categories": [
      "tech",
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "section_title": "股票首页_新浪财经_新浪网",
    "site_title": null,
    "title": "振东制药：参股公司在研药品Ⅲ期临床试验达到主要研究终点|振东制药_新浪财经_新浪网",
    "title_full": "振东制药：参股公司在研药品Ⅲ期临床试验达到主要研究终点|振东制药_新浪财经_新浪网",
    "published": "2025-07-31T07:11:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 236,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "62662f183b9ab44ca3a8f6a659a4bb538125d6de",
  "url": "https://finance.sina.com.cn/roll/2025-07-31/doc-infiitzy9202743.shtml",
  "ord_in_thread": 0,
  "author": "上海证券报",
  "published": "2025-07-31T07:11:00.000+03:00",
  "title": "振东制药：参股公司在研药品Ⅲ期临床试验达到主要研究终点|振东制药_新浪财经_新浪网",
  "text": "来源：上海证券报·中国证券网\n上证报中国证券网讯 7月30日晚 振东制药 发布公告称，公司参股的广东龙创基药业有限公司（以下简称“龙创基药业”）在研项目“阴道用乳杆菌二联活菌胶囊”的Ⅲ期临床试验达到主要研究终点。公司近期将递交上市许可申请前的沟通交流申请，积极推进胶囊上市进程。\n根据公告，该胶囊为复方制剂，主要成分为格氏乳杆菌和鼠李糖乳杆菌活菌，用于由菌群紊乱而引起的细菌性阴道病的治疗。相比传统抗生素治疗方案，具有差异化优势，存在显著未满足的临床需求，未来市场潜力较大。\n对此，振东制药表示，近期将就“阴道用乳杆菌二联活菌胶囊”治疗细菌性阴道病适应证向国家药品监督管理局药品审评中心递交上市许可申请前的沟通交流申请，积极推进上市进程。\n据悉，2024年1月振东制药决定增资龙创基药业获得其6.015%的股权，后续龙创基药业取得“阴道用乳杆菌二联活菌胶囊”生产批件，振东制药有权在其取得“阴道用乳杆菌二联活菌胶囊”生产批件后，受让强基药业持有的龙创基药业53.985%的股权，合计达60%股权。\n华福证券最新研报表示，龙创基药业的乳杆菌二联活菌治疗细菌性阴道病领域的研发进度处于行业领先，预计2025年有望读出3期数据并申请上市，成为全球近20年来获批上市的首个双联活菌制剂。（武斌）",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Science and Technology",
    "Economy, Business and Finance"
  ],
  "topics": [
    "Health->drug rehabilitation",
    "Health->health treatment and procedure",
    "Health->health organisation",
    "Science and Technology->biomedical science",
    "Science and Technology->biotechnology",
    "Science and Technology->medical research",
    "Economy, Business and Finance->products and services",
    "Economy, Business and Finance->healthcare industry"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-07-31T08:15:02.422+03:00",
  "updated": "2025-07-31T08:22:07.000+03:00"
}